AnalystsJoseph CatanzaroJoseph Catanzaro's Stock Forecasts
AnalystsJoseph Catanzaro
Analyst Ranking
Bottom 10%
#3827 out of 4241 analysts
Average Return
-10.58%
Win Rate
23%9 out of 39
Risk vs Reward
Poor
Good
Joseph Catanzaro's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Immunomedics IncIMMU | +235.60% | $26.18 | $87.86 | 2020-04-22 - 2020-10-22 | Strong Buy |
Ocular Therapeutix IncOCUL | +150.14% | $7.40 | $18.51 | 2020-03-04 - 2021-03-05 | Strong Buy |
Halozyme Therapeutics IncHALO | +145.03% | $19.97 | $48.92 | 2020-02-04 - 2021-02-05 | Strong Buy |
Ocular Therapeutix IncOCUL | +97.29% | $3.32 | $6.55 | 2022-05-09 - 2023-05-09 | Strong Buy |
Repare Therapeutics IncRPTX | +46.49% | $23.21 | $34.00 | 2020-07-13 - 2021-07-13 | Strong Buy |
Joseph Catanzaro Analyst Color
Get additional color on Joseph Catanzaro's coverage of popular stocks
Joseph Catanzaro's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Rain Oncology IncRAIN | 2 | Hold | $1.75 | +42.28% | Downgrades | 19 days ago |
Immunitybio IncIBRX | 2 | Hold | $4.00 | +40.85% | Downgrades | a month ago |
Exelixis IncEXEL | 1 | Strong Buy | $28.00 | +45.83% | Assumes | a month ago |
Halozyme Therapeutics IncHALO | 3 | Strong Buy | $46.00 | +35.45% | Upgrades | a month ago |
Schrodinger IncSDGR | 1 | Strong Buy | $60.00 | +63.76% | Assumes | a month ago |
Keros Therapeutics IncKROS | 1 | Strong Buy | $110.00 | +150.63% | Maintains | a month ago |
Immunogen IncIMGN | 1 | Strong Buy | $16.00 | -6.76% | Upgrades | a month ago |
Gilead Sciences IncGILD | 1 | Strong Buy | $105.00 | +34.41% | Assumes | a month ago |
I MabIMAB | 3 | Strong Buy | $25.00 | +696.18% | Maintains | 2 months ago |
Biomea Fusion IncBMEA | 2 | Strong Buy | $40.00 | -2.20% | Maintains | 2 months ago |
Iovance Biotherapeutics IncIOVA | 4 | Strong Buy | $14.00 | +77.44% | Upgrades | 4 months ago |
Day One Biopharmaceuticals IncDAWN | 2 | Strong Buy | $45.00 | +246.69% | Maintains | 5 months ago |
Catalyst Pharmaceuticals IncCPRX | 1 | Strong Buy | $20.00 | +72.12% | Maintains | 6 months ago |
Acrivon Therapeutics IncACRV | 1 | Strong Buy | $25.00 | +100.00% | Initiates Coverage On | 6 months ago |
Achilles Therapeutics PLCACHL | 2 | Strong Buy | $8.00 | +724.74% | Maintains | 6 months ago |
Oyster Point Pharma IncOYST | 1 | Hold | $11.00 | -1.52% | Downgrades | 7 months ago |
Cardiff Oncology IncCRDF | 2 | Strong Buy | $5.00 | +208.64% | Maintains | 9 months ago |
Harpoon Therapeutics IncHARP | 2 | Strong Buy | $7.00 | +856.28% | Maintains | 10 months ago |
Cytomx Therapeutics IncCTMX | 1 | Hold | $1.50 | -10.71% | Downgrades | a year ago |
Repare Therapeutics IncRPTX | 2 | Strong Buy | $30.00 | N/A | Maintains | a year ago |
Essa Pharma IncEPIX | 1 | Strong Buy | $20.00 | N/A | Maintains | a year ago |
Ocular Therapeutix IncOCUL | 2 | Strong Buy | $16.00 | N/A | Maintains | a year ago |
Connect Biopharma Holdings LtdCNTB | 1 | Hold | $1.50 | N/A | Downgrades | a year ago |
Sensei Biotherapeutics IncSNSE | 2 | Strong Buy | $10.00 | N/A | Maintains | a year ago |
Neoleukin Therapeutics IncNLTX | 1 | Strong Buy | $25.00 | N/A | Maintains | a year ago |
Aadi Bioscience IncAADI | 1 | Strong Buy | $675.00 | N/A | Initiates Coverage On | 2 years ago |
Figs IncFIGS | 1 | Strong Buy | $35.00 | N/A | Initiates Coverage On | 2 years ago |
Marker Therapeutics IncMRKR | 1 | Strong Buy | $60.00 | N/A | Initiates Coverage On | 2 years ago |
Seagen IncSGEN | 2 | Hold | $170.00 | N/A | Maintains | 2 years ago |
Immunomedics IncIMMU | 1 | Strong Buy | $40.00 | N/A | Maintains | 3 years ago |
Xbiotech IncXBIT | 2 | Strong Buy | $18.00 | N/A | Maintains | 3 years ago |
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.